Pathway Genomics has added the Illumina MiSeqDx to its fleet of next-generation sequencing systems.

 

 

 

Designed and validated for the clinical market, the benchtop sequencing system will optimize the company’s ability to develop and run diagnostic applications. It enables sample multiplexing, maximizing operator efficiency and increasing throughput.

“The acquisition of this vital piece of technology is a necessary step for us to maintain our commitment to clinical innovation,” said Jim Plante, Pathway Genomics’ founder and CEO.

“The acquisition of this vital piece of technology is a necessary step for us to maintain our commitment to clinical innovation,” said Jim Plante, Pathway Genomics’ founder and CEO.

Allowing for a highly efficient workflow with minimal hands-on time, the MiSeqDx prepares DNA for sequencing following a streamlined process that includes ready-to-use reagents.

“Our investment in the first FDA-cleared sequencer is part of our strategic plans to grow our next-generation sequencing capacity on multiple platforms for genetic testing,” said Ardy Arianpour, Pathway Genomics’ chief strategy officer. “We have a full suite of services ready to be launched on the MiSeqDx, which will include both single genes and comprehensive panels.”

“Our investment in the first FDA-cleared sequencer is part of our strategic plans to grow our next-generation sequencing capacity on multiple platforms for genetic testing,” said Ardy Arianpour, Pathway Genomics’ chief strategy officer. “We have a full suite of services ready to be launched on the MiSeqDx, which will include both single genes and comprehensive panels.”

Comments are closed.